Yael Gruper

Yael Gruper

Auto-generated profile, based on publicly available information

Yael Gruper

Department of Biomolecular Sciences, The Weizmann Institute of Science, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Cancer Discovery
Verified
Journal Article
Closed access
ABAviad Ben-Shmuel
Aviad Ben-Shmuel
YGYael Gruper
Yael Gruper
CHCoral Halperin
Coral Halperin
OLOshrat Levi-Galibov
Oshrat Levi-Galibov
HRHallel Rosenberg-Fogler
Hallel Rosenberg-Fogler
RSRuth Scherz-Shouval
Ruth Scherz-Shouval
Cancer-associated fibroblasts (CAF) are abundant components of the breast tumor microenvironment and major contributors to immune-modulation. CAFs regulate the activity of many immune cells including T cells, macrophages, and dendritic cells; however, little is known about their interaction with NK cells, which constitute an important arm of antitumor immunity. Using mouse models of breast cancer and ex vivo cocultures, we find that CAFs inhibit NK cell cytotoxicity toward cancer cells. We unravel the mechanism by which suppression occurs, which is through ligand–receptor engagement between NK cells and CAFs, leading to CAF cytolysis and downregulation of activating receptor expression on NK cells, promoting cancer cell escape from NK cell surveillance. In patients with triple-negative breast cancer, we find enrichment of NK cells in CAF-rich regions and upregulation of NK-binding ligands on CAFs, which correlates with poor disease outcomes. These results reveal a CAF-mediated immunosuppressive decoy mechanism with implications for the treatment of carcinomas. Significance: Little is known about the influence of CAFs on NK cells in the context of carcinomas. Here, we mechanistically unravel a pathway of CAF-mediated suppression of NK cells in breast cancer, opening possible avenues for new biomarkers and strategies for immune-based therapies. See related commentary by Sherman, p. 1096

3 September 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YGYael Goldfarb
Yael Goldfarb
TGTal Givony
Tal Givony
NKNoam Kadouri
Noam Kadouri
JDJan Dobeš
Jan Dobeš
CPCristina Peligero-Cruz
Cristina Peligero-Cruz
JAJakub Abramson
Jakub Abramson
The autoimmune regulator (AIRE) is essential for the establishment of central tolerance and prevention of autoimmunity. Interestingly, different AIRE mutations cause autoimmunity in either recessive or dominant-negative manners. Using engineered mouse models, we establish that some monoallelic mutants, including C311Y and C446G, cause breakdown of central tolerance. By using RNAseq, ATACseq, ChIPseq, and protein analyses, we dissect the underlying mechanisms for their dominancy. Specifically, we show that recessive mutations result in a lack of AIRE protein expression, while the dominant mutations in both PHD domains augment the expression of dysfunctional AIRE with altered capacity to bind chromatin and induce gene expression. Finally, we demonstrate that enhanced AIRE expression is partially due to increased chromatin accessibility of the AIRE proximal enhancer, which serves as a docking site for AIRE binding. Therefore, our data not only elucidate why some AIRE mutations are recessive while others dominant, but also identify an autoregulatory mechanism by which AIRE negatively modulates its own expression.

22 November 2023 in Nature
Verified
Journal Article
Closed access
PDF file
YGYael Gruper
Yael Gruper
AWAnette S. B. Wolff
Anette S. B. Wolff
LGLiad Glanz
Liad Glanz
FSFrantisek Spoutil
Frantisek Spoutil
MMMihaela Cuida Marthinussen
Mihaela Cuida Marthinussen
JAJakub Abramson
Jakub Abramson

2 September 2024 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YGYael Gruper
Yael Gruper
ABAviad Ben-Shmuel
Aviad Ben-Shmuel
RSRuth Scherz-Shouval
Ruth Scherz-Shouval

3 June 2025
Verified
Other
Open access
ABAviad Ben-Shmuel
Aviad Ben-Shmuel
YGYael Gruper
Yael Gruper
CHCoral Halperin
Coral Halperin
OLOshrat Levi-Galibov
Oshrat Levi-Galibov
HRHallel Rosenberg-Fogler
Hallel Rosenberg-Fogler
RSRuth Scherz-Shouval
Ruth Scherz-Shouval
Cancer-associated fibroblasts (CAF) are abundant components of the breast tumor microenvironment and major contributors to immune-modulation. CAFs regulate the activity of many immune cells including T cells, macrophages, and dendritic cells; however, little is known about their interaction with NK cells, which constitute an important arm of antitumor immunity. Using mouse models of breast cancer and ex vivo cocultures, we find that CAFs inhibit NK cell cytotoxicity toward cancer cells. We unravel the mechanism by which suppression occurs, which is through ligand–receptor engagement between NK cells and CAFs, leading to CAF cytolysis and downregulation of activating receptor expression on NK cells, promoting cancer cell escape from NK cell surveillance. In patients with triple-negative breast cancer, we find enrichment of NK cells in CAF-rich regions and upregulation of NK-binding ligands on CAFs, which correlates with poor disease outcomes. These results reveal a CAF-mediated immunosuppressive decoy mechanism with implications for the treatment of carcinomas.Significance:Little is known about the influence of CAFs on NK cells in the context of carcinomas. Here, we mechanistically unravel a pathway of CAF-mediated suppression of NK cells in breast cancer, opening possible avenues for new biomarkers and strategies for immune-based therapies.See related commentary by Sherman, p. 1096

3 June 2025
Verified
Other
Open access
PDF file
ABAviad Ben-Shmuel
Aviad Ben-Shmuel
YGYael Gruper
Yael Gruper
CHCoral Halperin
Coral Halperin
OLOshrat Levi-Galibov
Oshrat Levi-Galibov
HRHallel Rosenberg-Fogler
Hallel Rosenberg-Fogler
RSRuth Scherz-Shouval
Ruth Scherz-Shouval
Supplementary Figure 6 shows NK cell depletion in D2A1 inoculated mice